Bilastine composition for parenteral administration once daily

By adding β-cyclodextrin to parenteral antihistamines, the solubility and bioavailability of bilastine are improved, and the problems of slow onset of existing parenteral antihistamines are solved, and the problem of slow onset of effects and great side effects are achieved. Rapid, long-acting and tolerant allergic acute attack treatment.

CN118891045APending Publication Date: 2024-11-01FAES FARMA SA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202380021951.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-17
Filing Date
2023-02-16
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Existing parenteral antihistamines are slow to take effect in the treatment of allergic acute treatment and often lead to side effects such as drowsiness, dizziness and drowsiness. They lack effective and well-tolerated options, especially when immediate action is required.

Method used

An aqueous parenteral pharmaceutical composition is developed, comprising 0.96% to 2.60% bilastin and 10% to 30% beta-cyclodextrin at a pH of 3.0 to 7.2, administered by intravenous or intramuscular route. , significantly improves the solubility and bioavailability of the drug, reduces side effects, and achieves rapid onset and long-term effect.

Benefits of technology

The composition showed high efficiency and maintained for 24 hours in 15 minutes, avoiding the side effects of lethargy and drowsiness, and providing a more effective treatment for acute attacks of allergic reactions, suitable as a once-daily treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004994153580000021
    Figure BDA0004994153580000021
  • Figure BDA0004994153580000081
    Figure BDA0004994153580000081
  • Figure BDA0004994153580000221
    Figure BDA0004994153580000221
Patent Text Reader

Abstract

The present invention relates to aqueous parenteral pharmaceutical compositions and their use in the treatment and / or prevention of conditions mediated by the H1 histamine receptor, such as allergic conditions or diseases and allergic symptoms, in particular when immediate action is desired; the aqueous parenteral pharmaceutical composition comprises: a) from 0.96% to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof; b) from 10% to 30% w / v of a beta-cyclodextrin selected from the group consisting of an unmodified beta-cyclodextrin, a C1-C6 alkyl-beta-cyclodextrin, a C1-C6 hydroxyalkyl beta-cyclodextrin, a C1-C6 carboxyalkyl-beta-cyclodextrin, a carbonyl-beta-cyclodextrin, a C1-C6 sulfoalkyl ether beta-cyclodextrin, and mixtures thereof; wherein the composition has a pH value of 3.0 to 7.2, including both the lower limit and the upper limit of this range, and wherein the parenteral is selected from intravenous or intramuscular.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an aqueous pharmaceutical composition comprising bilastine and β-cyclodextrin suitable for once-daily parenteral administration, and the use thereof as an antihistamine and antiallergic pharmaceutical composition. Background Art

[0002] Antihistamines are compounds that are commonly used in the symptomatic treatment of various allergic diseases or disorders, since many of their symptoms (itchy eyes, runny nose, itchy skin, etc.) are caused by the action of histamine. In fact, antihistamines have been known for a long time, some of them even in the middle of the twentieth century, for the treatment of a variety of diseases and processes, such as allergic and non-allergic rhinitis and conjunctivitis; acute and chronic urticaria; control of itching and scratching of various dermatological (e.g. bites, dermatitis) and non-dermatological (e.g. metabolic itch) causes; symptomatic treatment of catarrhal respiratory infections and nonspecific coughs; motion sickness, nausea and dizziness, as well as for the minor treatment of insomnia and anorexia (lack of appetite).

[0003] Antihistamines are usually administered orally (as tablets, syrups, or drops) or topically (creams, eye drops, nasal sprays, or ear drops).

[0004] Oral antihistamines can provide relief from several symptoms of allergy, however they have a delayed onset of action when compared to topical ocular agents.

[0005] The surface route is suitable for eye, nose or skin diseases (eye drops, nasal sprays, creams, gels). If the allergic symptoms are mainly ocular, then the surface treatment shows the treatment of choice, because they are faster (in a few minutes) than systemic agents, and therefore can easily delay allergic responses. The surface antihistamines also show less adverse effects, because the serum level is negligible and the required dosage for penetrating the conjunctiva is lower from the surface use. However, the use of surface antihistamines is very limited to ocular allergic reactions, so such surface preparations can not be applied to a larger range of diseases with its corresponding symptoms.

[0006] Parenteral routes are commonly used to prevent or treat severe and acute attacks of allergic reactions. This approach can only be used with some first generation antihistamines, which are known to cause sedation and cognitive and psychomotor impairment. There is currently a lack of effective and well-tolerated options for parenteral treatment, especially when immediate action is needed or when preferred parenteral preparations, preparations suitable for short-term treatment as a monotherapy or preparations suitable for severe cases of histamine-mediated hypersensitivity reactions.

[0007] Documents EP 0818454 A1 and EP 0580541 A1 disclose benzimidazole compounds having selective H1 antihistamine activity and no arrhythmogenic effect. Patent application EP 3040334 A1 also discloses benzimidazole compounds having potent selective H1 antihistamine activity and lacking activity against the central nervous system and against the cardiovascular system.

[0008] A specific compound having the above properties is 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid, also known as bilastine, which has the following formula:

[0009]

[0010] It was developed by Faes Farma, Spain. Bilastine is a second generation H1 antagonist benzimidazole compound with no sedative side effects, no cardiotoxic effects, and no liver metabolism. In addition, bilastine has been shown to be effective in the symptomatic treatment of allergic rhinoconjunctivitis and urticaria.

[0011] WO 2019 / 141563 discloses ophthalmic pharmaceutical compositions comprising bilastine. These compositions require the presence of a gelling agent so that the composition provides a prolonged effect in the eye and are therefore not suitable for parenteral administration.

[0012] In the case of an allergy emergency, i.e. a severe event of a histamine-mediated type I hypersensitivity reaction, immediate action is required because topical preparations may not be sufficiently effective and oral antihistamines may not work within a reasonable time frame. Parenteral administration of antihistamines may provide a solution to the lack of agents for allergy emergencies, and in particular, intravenous and intramuscular preparations have been shown to be very suitable for rapid and effective treatment of acute attacks of allergies. To date, only three injectable antihistamines are known: Dexchlorpheniramine (trade name), Cetirizine hydrochloride (trade name and diphenhydramine (trade name — withdrew from the U.S. market — and several unbranded preparations).

[0013] Dexchlorpheniramine is the standard antihistamine for allergic emergencies. It is the only injectable antihistamine regulated in Europe, however, like other first generation H1 antihistamines, it can induce extreme drowsiness, dizziness, or sleepiness. In some cases, up to four daily doses of dexchlorpheniramine may be required.

[0014] Cetirizine is a second-generation antihistamine compound that was approved by the FDA for intravenous administration in October 2019.

[0015] Diphenhydramine is a first generation H1 antihistamine and has been approved by the FDA as an injectable formulation at a concentration of 50 mg diphenhydramine hydrochloride / mL, however, like other first generation H1 antihistamines, diphenhydramine can induce extreme drowsiness, dizziness, or sleepiness. In some cases, up to eight daily doses of dexchlorpheniramine may be required.

[0016] Other disclosures in the art for the treatment of acute allergic symptoms by administration of parenteral antihistamine preparations are very rare.

[0017] EP1005865B1 discloses a process for preparing an antihistamine and antiallergic composition, the process comprising 1) preparing a fine powdered blend of Nimesulide and Cetirizine, and 2) dissolving the homogenous blend in a solvent suitable for parenteral administration at a temperature of 25°C to 35°C.

[0018] R. Corcóstegui et al. (Drugs RD 2006, 7(4), 219-231) compared the in vivo antihistamine and antiallergic properties of bilastine, cetirizine and fexofenadine by different routes of administration (oral and intravenous) in various animal models. Bilastine in a tartaric acid solution was administered intravenously to rats five minutes before the induction of papules by intradermal injection of histamine, and the resulting increase in capillary permeability was determined as a measure of the intensity of the histamine-mediated allergic reaction. Due to the low water solubility of bilastine (about 0.5 mg / ml at pH 5 to 8), large amounts of the bilastine composition disclosed in this document would be required to administer a therapeutically effective dose, which would prevent its effective parenteral administration and the development of a pharmaceutically acceptable parenteral formulation. Of course, such a composition would not be suitable for once-daily administration.

[0019] Parenteral compositions comprising high concentrations of bilastine with an optimal pH suitable for once-daily treatment / prophylaxis as monotherapy or for the treatment / prophylaxis of severe cases of histamine-mediated type I hypersensitivity reactions (e.g., acute urticaria, chronic urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity reactions, anaphylaxis or angioedema) are not known in the art. Summary of the invention

[0020] The inventors of the present invention unexpectedly found that the parenteral formulation of the present invention results in rapid onset of drug action, very high efficacy and no side effects (compared to known commercial formulations, the formulation is virtually as safe as a placebo and does not produce somnolence or drowsiness).

[0021] These compositions allow very high bilastine concentrations and at a pH suitable for parenteral administration.

[0022] Unexpectedly, the formulations of the present invention were found to be more effective than known commercial formulations. In particular, the formulations of the present invention showed a significantly higher efficacy than intramuscular administration. (Strong antihistamines used in allergic emergency events, which can induce extreme drowsiness, dizziness or sleepiness) Better efficacy results. It is noteworthy that the formulations of the present invention do not induce drowsiness, do not induce dizziness, and do not induce sleepiness.

[0023] It is also unexpected that the formulations of the present invention, when administered by the intravenous or intramuscular route, result in at least one of: improved drug onset, improved efficacy, or fewer side effects when compared to other bilastine compositions, when compared to other routes of administration, or when compared to other antihistamine compositions administered by similar routes of administration.

[0024] Additionally, the compositions of the invention have been found to be effective within 15 minutes of administration and last for 24 hours, making them particularly useful when an immediate effect is required, such as in the prevention / treatment of acute type I hypersensitivity reactions (alone or as an adjunct therapy).

[0025] Furthermore, since effectiveness is maintained for up to 24 hours, the compositions of the present invention can be used for once-daily administration, in contrast to current injectable antihistamine treatments.

[0026] Thus, in a first aspect, the present invention provides an aqueous parenteral pharmaceutical composition comprising:

[0027] a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, and

[0028] b) 10% w / v to 30% w / v of a β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof, and

[0029] Wherein the pH of the composition is from 3.0 to 7.2, including both the lower and upper limits of the range, and wherein parenteral is selected from intravenous or intramuscular.

[0030] Another aspect of the present invention relates to the aqueous parenteral pharmaceutical composition according to the present invention for use as a medicament.

[0031] In another aspect, the present invention relates to an aqueous parenteral pharmaceutical composition according to the present invention for use in the treatment and / or prevention of an allergic disease or disorder or an allergic symptom.

[0032] Another aspect of the present invention relates to the use of the aqueous parenteral pharmaceutical composition of the present invention for the preparation of a medicament for the treatment and / or prevention of allergic diseases or disorders or allergic symptoms.

[0033] Another aspect of the present invention relates to a method for treating and / or preventing an allergic disease or disorder or an allergic symptom, the method comprising administering to a subject in need of such treatment and / or prevention a therapeutically effective amount of an aqueous parenteral pharmaceutical composition of the present invention.

[0034] These aspects and preferred embodiments thereof are additionally described further in the description and defined in the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The following mean plasma concentration / time profiles (0 to 24 hours) are shown: a) Oral Bilastine b) intramuscular (im) bilastine, c) intramuscular (im) and d) intravenous (iv) bilastine.

[0036] Figure 2 is shown in im bilastine, iv bilastine, im Plot comparing oral bilastine and placebo in terms of % reduction in wheal area induced by histamine injection relative to baseline. Curve im bilastine: relative to im P ≤ 0.001 (time data points ≥ 30 minutes) and ns (ns: not significant, P>0.05) at 15 minutes; P ≤ 0.001 (15 minutes, 30 minutes and 12 hours) relative to iv bilastine, and P>0.05 for the remaining data points; P ≤ 0.001 (all time data) relative to placebo. P ≤ 0.001 (15 min to 12 h), P ≤ 0.05 (24 h); P ≤ 0.001 (15 min to 12 h), P = 0.002 (24 h) relative to placebo. Curves Oral bilastine: P ≤ 0.001 (30 min, 45 min), P ≤ 0.05 (15 min, 1 h), ns (remaining parts) relative to im bilastine; P ≤ 0.001 (15 min to 1 h), P ≤ 0.05 (12 h), ns (remaining parts) relative to iv bilastine; P ≤ 0.001 (15 min to 1 h), P ≤ 0.05 (12 h), ns (remaining parts) relative to im P ≤ 0.001 (1 h to 12 h), P ≤ 0.05 (24 h), ns (remaining); P ≤ 0.001 (45 min to 24 h), P ≤ 0.05 (15 min, 30 min) relative to placebo. Relative to placebo, P ≤ 0.001 (15 min to 4 h, 9 h), P ≤ 0.05 (12 h, 24 h), ns (6 h).

[0037] Figure 3 is shown in im bilastine, iv bilastine, im Graph comparing oral bilastine and placebo in terms of % reduction in flare area caused by histamine injection relative to baseline. Curve im Bilastine: relative to im P ≤ 0.001 (45 min to 24 h) and ns at 15 and 30 min; P ≤ 0.001 (15, 30, and 45 min) and P ≤ 0.05 (1 h) relative to iv bilastine, ns for all remaining data points; P ≤ 0.001 relative to placebo (all time points). P ≤ 0.001 (15 min to 24 h); P ≤ 0.001 (15 min to 24 h) relative to placebo. Curves Oral bilastine: P ≤ 0.001 (45 min, 1 h), P ≤ 0.05 (15 min, 30 min, 24 h), ns (remaining parts) relative to im bilastine; P ≤ 0.001 (15 min to 1 h), P ≤ 0.05 (2 h, 24 h), ns (remaining parts) relative to iv bilastine; P ≤ 0.001 (15 min to 1 h), P ≤ 0.05 (2 h, 24 h), ns (remaining parts) relative to im P ≤ 0.001 (2 hours to 24 hours), P ≤ 0.05 (15 minutes, 30 minutes, 1 hour), ns (45 minutes); relative to placebo, P ≤ 0.001 (45 minutes to 24 hours), P ≤ 0.05 (30 minutes), ns (15 minutes). Curve im Relative to placebo, P ≤ 0.001 (30 min, 45 min), P ≤ 0.05 (15 min, 1 h, 4 h to 24 h), ns (2 h).

[0038] Figure 4 is shown in im bilastine, iv bilastine, im Graph comparing oral bilastine and placebo in terms of % reduction from baseline in VAS (Visual Analogue Scale) values ​​associated with the itchy sensation induced by histamine injection. Curve im bilastine: relative to im P ≤ 0.001 (2 h to 9 h) and ns (remaining); relative to iv bilastine, all time data points are ns; relative to placebo, P ≤ 0.001 (2 h, 4 h), P ≤ 0.05 (1 h, 6 h, 9 h), ns (remaining). Curve iv bilastine: relative to im P ≤ 0.05 (2 h, 4 h, 6 h), ns (remaining parts); P ≤ 0.001 (2 h), P ≤ 0.05 (1 h, 4 h), ns (remaining parts) relative to placebo. Curves Oral bilastine: ns (all data points) relative to im bilastine; ns (all data points) relative to iv bilastine; ns (all data points) relative to im P ≤ 0.001 (9 hours), P ≤ 0.05 (2 hours, 4 hours, 6 hours, 12 hours), ns (remaining parts); P ≤ 0.05 relative to placebo (2 hours to 24 hours), ns (15 minutes to 1 hour). P ≤ 0.05 relative to placebo (15 minutes), ns (rest).

[0039] Figure 5 It is shown that when using im bilastine, iv bilastine, im The absolute value of the improvement in sleepiness relative to baseline for oral bilastine and placebo. Curve im bilastine: relative to im P ≤ 0.05; ns relative to iv bilastine and placebo. Curve iv bilastine: relative to im ns; ns relative to placebo. Curves Oral bilastine: ns relative to im bilastine, iv bilastine and placebo (3 hours and 1.5 hours); relative to im P ≤ 0.05 (1.5 hours and 3 hours). Curve im Relative to placebo, P≤0.05 (1.5 hours), ns (3 hours). DETAILED DESCRIPTION

[0040] The term "alkyl" refers to a linear or branched alkane derivative containing 1 to 6 ("C1-C6 alkyl"), preferably 1 to 3 ("C1-C3 alkyl") carbon atoms and which is bonded to the rest of the molecule by a single bond. Some illustrative examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl.

[0041] The expression "pharmaceutically acceptable" refers to compositions and molecular entities that are physiologically tolerated and generally do not produce allergic reactions or similar adverse reactions such as gastric disorders, dizziness, etc. when administered to humans or animals. Preferably, the term "pharmaceutically acceptable" means that it is approved by a state or federal regulatory agency or included in the US Pharmacopoeia or other generally recognized pharmacopeia for use in animals and more particularly in humans.

[0042] In this application, unless otherwise stated, all percentages disclosed refer to w / v percentages.

[0043] When a range is indicated in this document, both the lower limit and the upper limit are included in the stated range.

[0044] All embodiments disclosed in relation to one aspect of the invention are applicable to the other aspects as well.

[0045] The inventors have unexpectedly discovered that the combination of bilastine and at least β-cyclodextrin is optimal for parenteral administration, showing rapid onset of action, virtually no side effects (especially in terms of drowsiness, which is a feature of other injectable antihistamine preparations currently approved by regulatory agencies), and excellent prolonged action at a systemic level, which for the first time allows the provision of a once-daily parenteral formulation comprising bilastine. Thus, the formulation of the present invention, when administered by the intravenous or intramuscular route, results in at least one of: improved drug onset, improved efficacy, or fewer side effects when compared to other bilastine compositions, when compared to other routes of administration, or when compared to other antihistamine compositions administered by similar routes of administration.

[0046] Thus, in a first aspect, the present invention provides an aqueous parenteral pharmaceutical composition comprising:

[0047] a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, and

[0048] b) 10% w / v to 30% w / v of a β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof, and

[0049] Wherein the pH of the composition is from 3.0 to 7.2, including both the lower and upper limits of the range, and wherein parenteral is selected from intravenous or intramuscular.

[0050] Bilastin

[0051] The aqueous parenteral composition of the present invention comprises bilastine of the following formula or a pharmaceutically acceptable salt or solvate thereof:

[0052]

[0053] The compound is 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid, also known as bilastine. The synthesis of bilastine has been described, for example, in documents EP 0818454A1, EP 0580541A1 and EP 3040334A1.

[0054] Bilastine may be in the form of a salt or a solvate, preferably a pharmaceutically acceptable salt or solvate.

[0055] By way of example, the salt can be an acid addition salt, a base addition salt or a metal salt, and can be synthesized from the parent compound by conventional chemical methods known to those skilled in the art. Such salts are usually prepared, for example, by reacting the free compound with a stoichiometric amount of a suitable base or acid in water or in an organic solvent or in a mixture of the two. Usually non-aqueous media such as ether, ethyl acetate, ethanol, acetone, isopropanol or acetonitrile are preferred. Some illustrative examples of acid addition salts include inorganic acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, etc., and organic acid addition salts such as acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, mesylate, p-toluenesulfonate, camphorsulfonate, etc. Some illustrative examples of base addition salts include inorganic base salts such as ammonium salts, and organic base salts such as ethylenediamine, ethanolamine, N, N-dialkyleneethanolamine, triethanolamine, glutamine, amino acid basic salts, etc. Some illustrative examples of metal salts include, for example, sodium, potassium, calcium, magnesium, aluminum, and lithium salts.

[0056] The term "solvate" according to the present invention is understood to mean any form of an active compound having another molecule (most likely a polar solvent) attached thereto by non-covalent bonding. Some examples of solvates include hydrates and alcoholates. Solvation methods are well known in the prior art.

[0057] The compounds of the present invention are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, in addition to the replacement of hydrogen by deuterium or tritium, or carbon by enriched 13 C or 14 C is replaced by carbon, or nitrogen is enriched 15 Except for the nitrogen substitution of N, compounds having the present structures are within the scope of the present invention.

[0058] In one embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in a pharmaceutical composition of the present invention at a concentration of 0.96% to 2.60% w / v. A concentration of 0.96% to 2.60% w / v means that 9.6 mg to 26.0 mg of bilastine or a pharmaceutically acceptable salt or solvate thereof is present in 1 mL of an aqueous composition. In one embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in a pharmaceutical composition of the present invention at a concentration of 1% to 2.6% w / v. In one embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in a pharmaceutical composition of the present invention at a concentration of 1.00% to 2.60% w / v.

[0059] In one embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in the pharmaceutical composition of the present invention at a concentration of 0.96% to 1.5% w / v. In one embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in the pharmaceutical composition of the present invention at a concentration of 0.96% to 1.50% w / v. In another embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in the pharmaceutical composition of the present invention at a concentration of 1.0% to 1.4% w / v. In another embodiment, bilastine or a pharmaceutically acceptable salt or solvate thereof is present in the pharmaceutical composition of the present invention at a concentration of 1.00% to 1.40% w / v. In one embodiment, the composition comprises 1.05% w / v to 1.35% w / v of bilastine or a pharmaceutically acceptable salt or solvate thereof. In another embodiment, the composition comprises 1.1% w / v to 1.3% w / v of bilastine or a pharmaceutically acceptable salt or solvate thereof, such as, for example, 1.14% w / v to 1.26% w / v, or even 1.2% w / v. In another embodiment, the composition comprises 1.10% w / v to 1.30% w / v of bilastine or a pharmaceutically acceptable salt or solvate thereof, such as, for example, 1.14% w / v to 1.26% w / v, or even 1.20% w / v.

[0060] In the present invention, unless otherwise specified or not feasible, values ​​should be considered to be rounded to the last specified decimal. For example, a number such as "1.10" includes a range of 1.095 to 1.104. Similarly, a value such as "1.5" includes a range of 1.45 to 1.54, or a value such as "1.0" includes a range of 0.95 to 1.04.

[0061] Accordingly, the mass of bilastine can be calculated from the % w / v value. In a specific embodiment, the pharmaceutical composition is a unit dose. In one embodiment, the pharmaceutical composition is a unit dose comprising 9.6 mg to 28.0 mg, or even 9.6 mg to 22.0 mg of bilastine. In another embodiment, the pharmaceutical composition is a unit dose comprising 10 mg to 18 mg of bilastine or 11 mg to 15 mg of bilastine.

[0062] In one embodiment, the volume of a unit dose of a composition of the invention is 0.5 to 1.5 mL. In another embodiment, the volume of a unit dose of a composition of the invention is 0.8 to 1.5 mL or even 0.8 to 1.2 mL.

[0063] The term "unit dose" refers to an amount administered to a subject or patient as a single dose.

[0064] It has been found that β-cyclodextrin increases the solubility of bilastine, allowing compositions with high concentrations of bilastine to be obtained. Bilastine or a pharmaceutically acceptable salt or solvate thereof is completely dissolved in the pharmaceutical composition of the invention, ie without any obvious signs of precipitation.

[0065] Bilastine concentration can be determined, for example, by UV spectrophotometry at 254 nm.

[0066] In one embodiment, bilastine or a salt or solvate thereof is the only active pharmaceutical ingredient in the composition of the present invention.

[0067] Cyclodextrin

[0068] Cyclodextrin (CD) is a ring structure composed of five or more β-D-pyranose units connected at the 1,4 positions, usually with 6 (α-cyclodextrin), 7 (β-cyclodextrin), 8 (γ-cyclodextrin) or 9 (δ-cyclodextrin) sugar units in one cyclodextrin molecule.

[0069] The MS value (mean molar substitution) is the average number of moles of substituents per mol of glucopyranose. For example, in the case of β-cyclodextrin, the degree of substitution / modification (DS) is the average number of substituents per β-cyclodextrin core and can be calculated by multiplying the MS value by 7 (β-cyclodextrin contains 7 sugar units per cyclodextrin molecule).

[0070] Both amorphous cyclodextrin and crystalline cyclodextrin are within the scope of the present application. The term "cyclodextrin" as used herein may refer to cyclodextrin or cyclodextrin derivatives. Cyclodextrins are commercially available or may be synthesized by methods well known in the art. Some examples of cyclodextrins include, but are not limited to, modified or unmodified alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and delta-cyclodextrin.

[0071] The cyclodextrin of the present invention is β-cyclodextrin. Derivatives of cyclodextrin, and in particular derivatives of β-cyclodextrin of the present invention include derivatives in which some or all of the OH groups are converted into OR groups. The derivatives include derivatives having C 1-6 Alkyl derivatives, such as methylated, ethylated, propylated and butylated cyclodextrins, wherein R is methyl, ethyl, propyl or butyl; and derivatives having C1-C6 hydroxyalkyl substituents, such as hydroxypropyl cyclodextrin or hydroxyethyl cyclodextrin, wherein R is -CH2CH(OH)CH3 or CH2CH2OH; branched cyclodextrins, such as maltose-linked cyclodextrins; cationic cyclodextrins; quaternary ammonium; anionic cyclodextrins, such as carboxymethyl cyclodextrin, cyclodextrin sulfate and cyclodextrin succinate; amphoteric cyclodextrins, such as carboxymethyl / quaternary ammonium cyclodextrins. Other specific modifications include one or more hydroxyalkyl ethers (e.g., R is C 1-6 Alkylene hydroxy) moiety; C1-C6 sulfoalkyl ether (eg, R is C 2-6 Alkylene SO3 - ) part; C1-C6 carboxyalkyl (eg R is C(O)C 1-6 alkyl) moieties; substituted phenoxy moieties; tryptophan moieties; or mixtures thereof. The total number of OR groups per cyclodextrin molecule is defined as the degree of substitution / modification.

[0072] In the present invention, the β-cyclodextrin is selected from unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof.

[0073] In one embodiment, the β-cyclodextrin is a C1-C6 alkyl-β-cyclodextrin. Preferred alkyl-β-cyclodextrins include: methyl-β-cyclodextrin, dimethyl-β-cyclodextrin, trimethyl-β-cyclodextrin, ethyl-β-cyclodextrin, diethyl-β-cyclodextrin, propyl-β-cyclodextrin, and butyl-β-cyclodextrin. In a more preferred embodiment, the β-cyclodextrin is selected from methyl-β-cyclodextrin or dimethyl-β-cyclodextrin. In the context of the present invention, when the term "alkyl-β-cyclodextrin" is used, this is meant to include β-cyclodextrins in which the alkyl portion is optionally substituted, but does not include hydroxyalkyl-β-cyclodextrin.

[0074] The C1-C6 alkyl β-cyclodextrin preferably has a degree of substitution / modification of 1 to 18, 3 to 16, 4 to 14, 4 to 12.6, and more preferably 4 to 6.

[0075] In another embodiment, the β-cyclodextrin is a C1-C6 hydroxyalkyl-β-cyclodextrin. Preferred hydroxyalkyl-β-cyclodextrins include: hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin (which is equivalent to 2-hydroxypropyl-β-cyclodextrin) and 2-hydroxybutyl-β-cyclodextrin. In a more preferred embodiment, the β-cyclodextrin is hydroxypropyl-β-cyclodextrin (2-hydroxypropyl-β-cyclodextrin; HPBCD or HP-β-CD).

[0076] C1-C6 hydroxyalkyl β-cyclodextrin, and in particular hydroxypropyl-β-cyclodextrin, preferably has a degree of substitution / modification of 1 to 14, more preferably 2 to 8. In another embodiment, the degree of substitution is 3 to 7, preferably 3 to 6.

[0077] In one embodiment, the hydroxyalkyl β-cyclodextrin, and in particular hydroxypropyl-β-cyclodextrin, preferably has an average molar degree of substitution of 0.42 to 0.86, or 0.50 to 0.75.

[0078] In another embodiment, the β-cyclodextrin is C1-C6 carboxyalkyl-β-cyclodextrin. Preferred C1-C6 carboxyalkyl-β-cyclodextrins for use herein include carboxymethyl-β-cyclodextrin and (2-carboxyethyl)-β-cyclodextrin.

[0079] In another embodiment, the β-cyclodextrin is a C1-C6 sulfoalkyl ether β-cyclodextrin.The preferred sulfoalkyl ether-β-cyclodextrin for use herein is sulfobutyl ether-β-cyclodextrin.

[0080] The sulfoalkyl ether-β-cyclodextrin preferably has a degree of substitution / modification of 1 to 14, preferably 1 to 7.

[0081] In one embodiment, the β-cyclodextrin is selected from C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof.

[0082] In a preferred embodiment, the β-cyclodextrin is a pharmaceutically acceptable β-cyclodextrin.

[0083] In a specific embodiment, β-cyclodextrin is present in the composition in an amount of 10% to 30% w / v. Here, w / v means weight / volume percentage concentration (g / 100 mL), for example, when β-cyclodextrin is present in the composition in an amount of 10% to 30% w / v, this means that 100 mg to 300 mg of β-cyclodextrin is present in every 1 mL of the aqueous composition.

[0084] In some specific embodiments, β-cyclodextrin is present in an amount of 10% to 25% w / v. In another embodiment, β-cyclodextrin is present in an amount of 12% w / v to 22% w / v, or 15% w / v to 20% w / v. In another embodiment, β-cyclodextrin is present in an amount of 16% to 18% w / v (e.g., such as 17% w / v).

[0085] In another embodiment, the pharmaceutical composition is a unit dose comprising 100 to 330 mg β-cyclodextrin. In another embodiment, the pharmaceutical composition is a unit dose comprising 100 to 200 mg β-cyclodextrin or even 150 to 200 mg β-cyclodextrin.

[0086] In another embodiment, the pharmaceutical composition is a unit dose comprising 9.6 to 28 mg bilastine and 100 to 330 mg β-cyclodextrin. In another embodiment, the pharmaceutical composition is a unit dose comprising 10 to 18 mg bilastine or 11 to 15 mg bilastine and 100 to 200 mg β-cyclodextrin or even 150 to 200 mg β-cyclodextrin.

[0087] pH

[0088] The aqueous pharmaceutical composition of the present invention has been developed for parenteral use and / or administration, i.e., the aqueous parenteral pharmaceutical composition is suitable for these purposes. pH is an important aspect of parenteral formulations, which should have a pH close to physiological pH. However, a compromise can be found between the pH that ensures the stability of the drug substance and the physiological pH, since the pH can have an impact on the stability of the formulation. Due to potential irritation issues, the acceptable range for intravenous and intramuscular injections is pH 3 to 9. Inappropriate pH can promote local irritation and increase pain during administration.

[0089] In one embodiment, the pH of the pharmaceutical composition is between 3.0 and 7.2, including both lower and upper limits. In one embodiment, the pH of the pharmaceutical composition is between 4.0 and 7.2, including both lower and upper limits. In another embodiment, the pH of the pharmaceutical composition is between 4.0 and 7.0, including both lower and upper limits. In another embodiment, the pH of the composition of the present invention is between 4.0 and 6.0, including both lower and upper limits, such as 4.5 to 5.5. In some embodiments, the pH of the composition of the present invention is

[0090] 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1 or 7.2.

[0091] In one embodiment, the pH of the composition is 5. In the context of pH values, it must be readily understood that a pH value of 5 can also be considered to correspond to a pH range of 4.5 to 5.4.

[0092] The composition may contain a pH adjusting agent to obtain a desired pH value for the composition.

[0093] In one embodiment, the composition comprises a pH adjusting agent selected from the group consisting of hydrochloric acid, boric acid, acetic acid, sodium hydroxide, potassium hydroxide, or a combination thereof. Preferably, the pH adjusting agent is selected from the group consisting of hydrochloric acid, boric acid, acetic acid, and mixtures thereof; more preferably, it is hydrochloric acid, such as concentrated hydrochloric acid (37% w / w).

[0094] The pH may be determined by measuring the pH directly in the composition using conventional methods, such as using a pH electrode, preferably at 23°C.

[0095] Additional embodiments

[0096] The composition of the present invention also comprises a balance of water. That is, it comprises water to achieve the desired final volume of the composition.

[0097] The water in the composition of the present invention is preferably water for injection, such as distilled and / or sterile water for injection.

[0098] The term "water for injection" refers to water that has been purified to make it suitable for parenteral administration, such as water that meets the USP (or foreign equivalent) requirements for water for injection.

[0099] The compositions of the present invention may also include pharmaceutically acceptable parenteral carriers or excipients. By way of some non-limiting examples, suitable pharmaceutically acceptable parenteral excipients or carriers include: preservatives (including antimicrobial preservatives and chemical preservatives), tonicity agents, buffers, antioxidants, chelating agents, fillers, solubilizers, surfactants, cosolvents, and combinations thereof. Suitable pharmaceutical carriers or excipients are described in, for example, "Remington's Pharmaceutical Sciences" by EW Martin, the 21st edition, 2005.

[0100] Preservatives may include benzalkonium chloride, benthezonium chloride, benzyl alcohol, benzoic acid, chlorobutanol, m-cresol, methylparaben, propylparaben, butylparaben, phenol, 2-phenoxyethanol, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric borate, thimerosal, and mixtures thereof.

[0101] Commonly used tonicity agents are sodium chloride, dextrose, glycerol, glycerine, mannitol, potassium chloride, propylene glycol, and mixtures thereof.

[0102] Buffers may include citric acid / sodium citrate / disodium citrate / trisodium citrate, phosphoric acid / sodium phosphate / potassium phosphate, sodium acetate / acetic acid / glacial acetic acid / ammonium acetate, sodium hydroxide, tris acetate, ammonium sulfate, ammonium hydroxide, arginine, benzenesulfonic acid, sodium benzoate / benzoic acid, sodium bicarbonate, boric acid / sodium borate, sodium carbonate, carbon dioxide, diethanolamine, glucono delta lactone, glycine / glycine HCl, histidine / histidine HCl, hydrochloric acid, hydrobromic acid, lysine, maleic acid, meglumine, methanesulfonic acid, monoethanolamine, sodium succinate / disodium succinate, sulfuric acid, sodium tartrate / tartaric acid, tromethamine, and mixtures thereof.

[0103] Antioxidants can include ascorbic acid, acetylcysteine, ascorbyl palmitate, sodium ascorbate, butylated hydroxytoluene, butylated hydroxyanisole, citric acid, monothioglycerol, sulfites (bisulfites, metabisulfites), methionine, sodium metabisulfite, potassium metabisulfite, acetonemetabisulfite, cysteine ​​hydrochloride, sodium dithionite, gentisic acid, sodium glutamate, glutathione, monothioglycerol, propyl gallate, sodium sulfite, sodium bisulfite, sodium formaldehydesulfoxylate, thiourea, alpha tocopherol, and mixtures thereof.

[0104] Chelating agents may include disodium edetate, sodium edetate, calcium disodium edetate, DTPA, citric acid monohydrate, calcium versetamide, calteridol, ethylenediaminetetraacetic acid, and mixtures thereof.

[0105] Bulking agents may include mannitol, sucrose, lactose, dextran, trehalose, sorbitol, glucose, raffinose, glycine, histidine, and mixtures thereof.

[0106] Solubilizers, surfactants and co-solvents may include surfactants such as polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monooleate polyoxyethylene sorbitan monolaurate (Tween 20), lecithin, polyoxyethylene-polyoxypropylene copolymer (Pluronic), and alcohols such as ethanol, benzyl benzoate, dimethylacetamide, glycerol, sorbitol, polyethylene glycol, pyrrolidone, propylene glycol, castor oil, soybean oil, cottonseed oil, safflower oil, sesame oil, peanut oil, poppyseed oil, vegetable oil, and mixtures thereof.

[0107] In one embodiment, the pharmaceutical composition of the present invention may include an additional pharmaceutically acceptable parenteral carrier or excipient in an amount of 0% to 50% w / v, 0% to 40% w / v, or even 0% to 30% w / v. That is, the composition may not include an additional pharmaceutically acceptable parenteral carrier or excipient (0% w / v), or may include an additional pharmaceutically acceptable parenteral carrier or excipient in an amount of 50% w / v, 40% w / v, or 30% w / v, respectively. In a specific embodiment, the pharmaceutical composition of the present invention may include an additional pharmaceutically acceptable parenteral carrier or excipient in an amount of 0 to 20% w / v, or even 0 to 10% w / v.

[0108] The expression "pharmaceutically acceptable excipient" refers to a carrier, diluent or adjuvant with which an active ingredient is administered.

[0109] In one embodiment, the composition of the present invention does not include a gelling agent, such as hyaluronic acid, gellan gum, guar gum, locust bean gum, alginic acid, povidone, kappa-carrageenan, alginate gum, dextran, dextran sulfate, chitosan, or salts thereof.

[0110] In a particular embodiment, the composition of the invention does not comprise hyaluronic acid or a salt thereof.

[0111] In one embodiment, the composition of the invention consists of:

[0112] a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof,

[0113] b) 10% w / v to 30% w / v of β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof,

[0114] c) a pH adjusting agent for providing a pH value of 3.0 to 7.2, including both the lower and upper limits of the range,

[0115] d) water for injection, and

[0116] e) optionally, one or more pharmaceutically acceptable parenteral excipients or carriers selected from the group consisting of preservatives, tonicity agents, buffers, antioxidants, chelating agents, fillers, solubilizers, surfactants, co-solvents, and mixtures thereof, including antimicrobial preservatives and chemical preservatives.

[0117] In one embodiment, the additional pharmaceutically acceptable parenteral excipient or carrier is present in the composition in an amount of 0% to 50% w / v, or in an amount of 0% to 40% w / v, or in an amount of 0% to 30% w / v. In one embodiment, the additional pharmaceutically acceptable parenteral excipient or carrier is present in the composition in an amount of 0% to 20% w / v, or in an amount of 0% to 10% w / v.

[0118] Preferably, the term one or more refers to 1 to 5, or 1 to 4. In one embodiment, it refers to 1, 2 or 3.

[0119] According to a specific embodiment, the composition of the present invention consists of:

[0120] a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof,

[0121] b) 10% w / v to 30% w / v of β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof,

[0122] c) a pH adjuster for providing a pH value of 3.0 to 7.2, including both the lower and upper limits of the range, and

[0123] d) Water for injection.

[0124] In one embodiment, the pharmaceutical composition of the present invention is a once-daily pharmaceutical composition.

[0125] The pharmaceutical composition of the present invention is suitable for parenteral administration. In particular, it is suitable for intramuscular or intravenous administration, preferably intramuscular administration.

[0126] The term "parenteral" refers to any method of administering a drug to a patient that does not involve the digestive tract. The term "parenteral" comes from the Greek: "para" means beside or alongside, and "enteron" means intestine.

[0127] In the present invention, the term "parenteral" is selected from intramuscular administration and intravenous administration.

[0128] The present invention relates to antihistamine compositions that exhibit rapid onset of action. In this sense, routes of administration such as intradermal will result in a slow onset of action. In such cases, the inventors believe that the presence of excipients such as gelling agents will produce an even slower onset of action.

[0129] In one embodiment, the pharmaceutical composition of the present invention is not suitable for subcutaneous administration or intradermal administration. In another embodiment, the pharmaceutical composition of the present invention is not suitable for at least one of the following: subcutaneous administration, intrathecal administration, intraarterial administration, intradermal administration, intraocular administration or subconjunctival administration.

[0130] Both subcutaneous and intradermal administration routes are administered by injection into the skin between the epidermis and the dermis. Subcutaneous administration is usually administered at an angle of 45°, while intradermal administration is usually administered at an angle of 10° to 15°. In both subcutaneous and intradermal administration routes, the volume injected is less than 0.5 mL, usually less than 0.3 mL, and preferably less than 0.2 mL. Compared to subcutaneous or intradermal administration routes, the volume injected in intramuscular or intravenous administration is usually equal to or greater than 0.3 mL, 0.5 mL, 0.75 mL or 1 mL.

[0131] In a specific embodiment, the pharmaceutical composition of the present invention is administered parenterally, wherein the injection volume is 0.5 to 5 mL, 0.5 to 4 mL, 0.5 to 3 mL, 0.5 to 2 mL, 0.5 to 1.5 mL, preferably 0.7 to 1.5 mL, more preferably 0.8 to 1.2 mL, and even more preferably 0.9 to 1.1 mL.

[0132] The present invention relates to parenteral administration, which consists of intramuscular or intravenous administration. Compared to subcutaneous or intradermal administration routes, intramuscular administration is given at an angle greater than 45°, preferably at an angle of 70° to 90°, more preferably at an angle of 80° to 90°, and most preferably at an angle of 90° relative to the skin. The skilled person will readily understand the angle required to administer the composition intramuscularly. Intravenous administration is typically given at an angle of 25°.

[0133] Common muscle sites for intramuscular administration are the buttocks, thigh, or shoulder muscles.

[0134] use

[0135] Bilastine has been found to be an antagonist of the histamine H1 receptor and is therefore useful in the treatment and / or prevention of diseases known to be susceptible to improvement by histamine H1 receptor antagonism.

[0136] Therefore, one aspect of the present invention relates to an aqueous parenteral pharmaceutical composition according to the present invention for use as a medicament.

[0137] Another aspect of the invention relates to an aqueous parenteral pharmaceutical composition of the invention for use in the treatment and / or prevention of diseases, disorders or conditions susceptible to improvement by antagonism of histamine H1 receptors. Such diseases, disorders or conditions are, for example, allergic diseases, allergic conditions and symptoms derived from allergic reactions.

[0138] In a preferred embodiment, the present invention relates to an aqueous parenteral pharmaceutical composition of the present invention for use in the treatment and / or prevention of an allergic disease, an allergic condition or an allergic symptom. Preferably, the allergic disease, allergic condition or allergic symptom is selected from the group consisting of rhinitis, conjunctivitis, rhinoconjunctivitis, hay fever, dermatitis, eczema, erythema, pruritus, itching, urticaria, chronic urticaria, asthma, allergic reaction, acute urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity reaction, angioedema, food allergy or drug allergy.

[0139] In one embodiment, the composition of the present invention is used to prevent and / or treat histamine-mediated type I hypersensitivity reactions, such as allergic rhinitis, conjunctivitis, rhinoconjunctivitis, asthma, dermatitis, urticaria, acute urticaria, chronic urticaria, anaphylaxis, angioedema, food allergy, drug allergy, hay fever, eczema, erythema, pruritus or itching. In a preferred embodiment, the composition is used to prevent and / or treat acute urticaria, chronic urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity, anaphylaxis or angioedema.

[0140] In the present invention, the parenteral route (IM or IV) can be used to prevent or treat severe and acute attacks of allergic reactions. In a preferred embodiment, the composition of the present invention is used for the short-term treatment of histamine-mediated type I hypersensitivity reactions, preferably selected from acute urticaria. The composition of the present invention can also be used as an additional treatment in severe cases.

[0141] The term short-term treatment in conjunction with a rapid onset of action is understood to mean a treatment whose effect is evident within the first 20 minutes, preferably within the first 15 minutes, after the start of administration.

[0142] Since the compositions of the present invention are rapid in onset and very effective, they can be used in severe or acute cases, and / or cases where an immediate effect is desired. The compositions can also be used when parenteral administration is necessary or preferred, such as in uncooperative, nauseous or unconscious patients. In addition, since the duration of action of the compositions of the present invention is prolonged, they can be administered as a once-daily composition.

[0143] The term "once daily" is well known to those skilled in the art and is intended to mean that the dose is administered to a subject once daily, i.e., approximately once every 24 hours. In other words, once daily means that two intravenous or intramuscular injections of the pharmaceutical composition must be separated in time by at least 24 hours.

[0144] Therefore, in one embodiment, the present invention relates to an aqueous parenteral pharmaceutical composition according to the present invention for use in the treatment and / or prevention of an allergic disease, an allergic disorder or an allergic symptom, wherein the composition is administered once daily.

[0145] Generally, the effective amount of a compound of the invention will depend on the severity of the condition to be treated and / or prevented and the weight of the patient. However, a typical total daily dose may be from 9.6 mg to 15.0 mg of bilastine.

[0146] Therefore, in one embodiment, the present invention relates to an aqueous parenteral pharmaceutical composition of the present invention for the treatment and / or prevention of allergic diseases, allergic conditions or allergic symptoms, wherein the total amount of bilastine administered daily is 9.6 mg to 15.0 mg; preferably, wherein the total amount of bilastine administered once daily is 9.6 mg to 15.0 mg.

[0147] In another embodiment, the total daily dose of bilastine may be from 10.0 mg to 14.0 mg or from 11.0 mg to 13.0 mg.

[0148] The parenteral pharmaceutical composition of the present invention can be used for the prevention and / or treatment of an object or patient, wherein the object or patient is a mammal, preferably a human, including humans of any age, race and gender. In one embodiment, the composition of the present invention is used as a monotherapy for the treatment and / or prevention of the above-mentioned diseases, disorders or conditions. That is, bilastine is used as the sole active pharmaceutical ingredient in the prevention and / or treatment.

[0149] In another embodiment, the composition of the present invention is used as an adjunctive therapy, i.e., in combination with another active pharmaceutical ingredient. In one embodiment, the composition of the present invention is used in combination with adrenaline, a β2 agonist (e.g., salbutamol or albuterol), an H2 antihistamine (e.g., cimetidine or famotidine), a glucocorticoid (e.g., dexamethasone, methylprednisolone, or hydrocortisone), a vasopressor (e.g., norepinephrine), phenylephrine, dopamine, dobutamine, or vasopressin, or glucagon, e.g., for the treatment of a serious disease, disorder, or condition, such as an allergic reaction.

[0150] The pharmaceutical composition of the present invention can be administered by parenteral administration. In a specific embodiment, it is administered intramuscularly or intravenously, preferably intramuscularly.

[0151] In the context of this specification, the term "treatment" or its variants means the administration of a composition according to the invention to improve or eliminate a disease or one or more symptoms associated with the disease."Treatment" also encompasses improving or eliminating the physiological sequelae of the disease.

[0152] The term "improvement" in the context of the present invention is to be understood as meaning any improvement in the condition of the patient being treated.

[0153] In the context of the present specification, the term "prevention" or variations thereof means administering a composition according to the present invention to reduce the risk of acquiring or developing a disease or one or more symptoms associated with the disease.

[0154] The expression "aqueous parenteral pharmaceutical composition" refers to a liquid pharmaceutical composition which comprises water and is suitable for parenteral administration.

[0155] The expression "therapeutically effective amount" means an amount of a drug that, when administered, supplies an amount of one or more pharmaceutically active agents contained therein to provide a therapeutic benefit in the treatment or management of a disease or disorder.

[0156] In a particular embodiment, the pharmaceutical composition of the invention is not suitable for cosmetic use, ie it is not suitable for non-therapeutic use.

[0157] Some specific implementation plans

[0158] Specific embodiments 1. An aqueous parenteral pharmaceutical composition comprising:

[0159] a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, and

[0160] b) 10% w / v to 30% w / v of a β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof, and

[0161] The pH value of the composition is 3.0 to 7.2, including both the lower and upper limits of the range.

[0162] Embodiment 2. The pharmaceutical composition according to embodiment 1, wherein the composition does not contain a gelling agent.

[0163] Embodiment 3. A pharmaceutical composition according to any one of Embodiments 1 to 2, wherein the composition consists of:

[0164] a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof,

[0165] b) 10% w / v to 30% w / v of β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof,

[0166] c) a pH adjusting agent for providing a pH value of 3.0 to 7.2, including both the lower and upper limits of the range,

[0167] d) water, and

[0168] e) optionally, one or more pharmaceutically acceptable parenteral excipients or carriers selected from the group consisting of preservatives, tonicity agents, buffers, antioxidants, chelating agents, fillers, solubilizers, surfactants, co-solvents, and mixtures thereof, including antimicrobial preservatives and chemical preservatives.

[0169] Embodiment 4. The pharmaceutical composition according to any one of Embodiments 1 to 3, wherein the composition comprises 1.0% w / v to 1.4% w / v of bilastine or a pharmaceutically acceptable salt or solvate thereof.

[0170] Embodiment 5. A pharmaceutical composition according to any one of Embodiments 1 to 4, wherein the composition comprises 1.05% w / v to 1.35% w / v of bilastine, or 1.10% w / v to 1.30% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof.

[0171] Embodiment 6. A pharmaceutical composition according to any one of Embodiments 1 to 5, wherein the composition comprises 10% w / v to 25% w / v of β-cyclodextrin.

[0172] Embodiment 7. A pharmaceutical composition according to any one of Embodiments 1 to 6, wherein the composition comprises 12% w / v to 22% w / v, or 15% w / v to 20% w / v of β-cyclodextrin.

[0173] Specific embodiment 8. The pharmaceutical composition according to any one of specific embodiments 1 to 7, wherein the β-cyclodextrin is C1-C6 hydroxyalkyl β-cyclodextrin, preferably hydroxypropyl β-cyclodextrin.

[0174] Embodiment 9. The pharmaceutical composition according to any one of Embodiments 1 to 8, wherein the pH value of the composition is 4.0 to 7.0, preferably 4.0 to 6.0.

[0175] Embodiment 10. A pharmaceutical composition according to any one of Embodiments 1 to 9, wherein the composition comprises:

[0176] a) 1.0% w / v to 1.4% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, and

[0177] b) 10% w / v to 25% w / v of C1-C6 hydroxyalkyl β-cyclodextrin, such as hydroxypropyl β-cyclodextrin, and

[0178] The pH value of the composition is 4 to 6, including both the lower and upper limits of the range.

[0179] Embodiment 11. The pharmaceutical composition according to any one of Embodiments 1 to 10 for use as a medicament.

[0180] Embodiment 12. The pharmaceutical composition according to any one of Embodiments 1 to 10, for use in the treatment and / or prevention of allergic diseases or disorders or allergic symptoms.

[0181] Embodiment 13. A pharmaceutical composition for use according to any one of embodiments 11 to 12 for the treatment and / or prevention of rhinitis, conjunctivitis, rhinoconjunctivitis, hay fever, dermatitis, eczema, erythema, pruritus, itching, urticaria, asthma, allergic reaction, acute urticaria, chronic urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity reaction, angioedema, food allergy or drug allergy.

[0182] Embodiment 14. The pharmaceutical composition for use according to any one of embodiments 11 to 13, wherein the composition is administered by intravenous or intramuscular administration.

[0183] Embodiment 15. The pharmaceutical composition for use according to any one of embodiments 11 to 14, wherein the composition is administered once daily.

[0184] The following examples are merely illustrative of certain embodiments of the invention and are not to be construed as limiting the invention in any way.

[0185] Example

[0186] Materials and methods

[0187] The following materials were used: bilastine (Faes Farma, batch number 5000015521); hydroxypropyl-β-cyclodextrin (HPβCD, Kleptose parenteral Roquette Pharma, molar substitution 0.65, molecular weight 1399, batch number 1605157); HCl 37% (VWR Prolabo; batch number 11E230022); 0.22 μm membrane filter MCE membrane, 33 mm diameter) and 0.45 μm sterile filter Nylon membrane, 2mL clear type II glass ampoule.

[0188] The water used in the following examples was from Merck-Millipore Purified water obtained from water purification system. Use The solution was stirred with a multi-point magnetic stirrer.

[0189] The pH of the solutions was determined by a Hanna HI5222 pH meter with a HI1330B micro pH electrode.

[0190] By The concentration of bilastine in the solubility test was determined by UV / vis spectrophotometer at 60 UV-VIS.

[0191] The concentration of bilastine in the stability test was determined by HPLC (Merck Hitachi, Germany) equipped with a diode array detector (L-4500, Merck Hitachi), a compatible pump (L6200 A, Merck Hitachi) and an autosampler (AS4000 A, Merck Hitachi) equipped with a system injection of 100 μl capacity, a control module (Model D-6500, Hitachi) and Model D-7000 HMS Version 4.0 data processing software (Merck Hitachi). Chromatographic analysis was performed using a Waters Symmetry C18 column (3.9×150 mm, 5 μm particle size) maintained at 30° C. by a column thermostat (L-5025, Merck).

[0192] An autoclave from a Raypa steam sterilizer (Terrassa, Spain) was used to determine the thermal stability of the formulations.

[0193] The formulation stability was tested in a 5°C ± 3 climate chamber (brand: ERATIS, model: ICH2000), a 40°C / 75% RH climate chamber (brand: INELTEC, model: CCLR-0 / 1360) and a 25°C / 60% RH climate chamber (code CAM027).

[0194] Example 1. Solubility of Bilastine vs. HPβCD Concentration and pH

[0195] The solubility of bilastine was determined at different HPβCD concentrations and pH values.

[0196] The desired amount of HPβCD was dispersed in 40 ml of purified water in a 50 ml flask until completely dissolved and further diluted with water until the final volume was 50 ml. Each solution was divided into three solutions (15 ml each) and the pH was adjusted to the desired value (3, 5 or 7, respectively) with HCl 37%. Each solution was transferred to three vials (5 mL solution each) again so that each sample was repeated several times. An excess of bilastine was added to each vial and the solution was kept under magnetic stirring for 24 hours. After this time, the pH was adjusted again and it was kept stirring for another 24 hours. Finally, the mixture was filtered through a 0.45 μm filter. Nylon membrane, The samples were filtered, the final pH was checked, and the concentration was determined by UV spectrophotometry at a wavelength of 254 nm. Statistical analysis of the results was performed using Centurion XVI Statgraphics program version 16.1.15. The results are shown in the table below.

[0197]

[0198] Very high bilastine concentrations were obtained for the compositions tested.

[0199] Example 2. Stability of Bilastine Formulations

[0200] Eight batches (denoted as Formulations A to I) with different HPβCD concentrations and pH adjustments were prepared for preliminary stability studies at three different conditions (5°C ± 3°C; 25°C / 60% RH; and 40°C / 75% RH) for six months.

[0201] Batch A was prepared as follows. 40 ml of purified water was placed in a mixing flask and 10 g of HPβCD was added under continuous stirring until completely dissolved. The solution was diluted with purified water until the final volume was 50 mL. To this solution was added 1.2 g of bilastine and the solution was stirred for 1 hour. HCl 37% was added until the bilastine was completely dissolved. Finally, the pH was adjusted to 4 with HCl 37%.

[0202] The samples were filtered through a 0.22 μm membrane filter (sterile filtration, Filters, MCE membranes, Filter and place directly into final ampoule (2 ml volume). This process is performed in a laminar flow hood using sterile materials. Finally, take a sample for analysis.

[0203] The same method was used to prepare Batches B to I having the compositions shown in the following table.

[0204]

[0205] The initial stability study was conducted for 6 months, but the formulations were analyzed at 0, 1, 2, 3 and 6 months to examine the following parameters: macroscopic inspection of encapsulation, appearance and color of the solution, presence / absence of visible particles, pH and concentration of bilastine.

[0206] To analyze pH and bilastine concentration, open the ampoule and pass through a sterile 0.45 μm filter. Nylon membrane, The content was filtered. The concentration of bilastine (mg / mL) was determined by HPLC (Phase A 58%: acetonitrile / methanol; Phase B 42%: 10 mM bicarbonate buffer).

[0207] The results for bilastine concentration and pH are shown in the table below (only results at 0, 3 and 6 months are shown).

[0208]

[0209] All formulations were found to be stable. The best stability results after 6 months were found for formulation H (12 mg / ml bilastine, 17% HPβCD, pH 5.1) and formulation D (24 mg / ml bilastine, 25% HPβCD, pH 4.5).

[0210] Example 3. Thermal stability study

[0211] In order to verify that the samples can be sterilized with the terminal sterilization process of the autoclave, a new batch of preparation H (12 mg / ml bilastine, 17% HPβCD, pH 5.1) and its placebo (same composition without bilastine) were prepared. Both preparations were packaged in 2 mL I-type transparent glass ampoules and sterilized by autoclave at 121° C. during 15 minutes. The samples were analyzed by HPLC. Then, preparation H and its placebo with and without the terminal sterilization process were compared.

[0212] No differences were found between Formulation H and the placebo formulation before and after the autoclave sterilization process. Therefore, the thermal stability study showed that terminal sterilization in autoclave did not affect the stability of the formulations.

[0213] Example 4. Preparation of pharmaceutical composition

[0214] Pharmaceutical compositions containing bilastine used in the following examples were prepared as follows.

[0215] Bilastine concentration 12 mg / ml (1.2% w / v) and bilastine 0 mg / ml (placebo) batches were prepared under GMP conditions for investigational drug products.

[0216] The clinical batch sizes of bilastine 12 mg / ml parenteral solution and placebo were 80 L each.

[0217] The formulations for the preparation of the drug product and placebo are described in the following table.

[0218] Pharmaceutical products

[0219]

[0220] Placebo formulation

[0221]

[0222] The formulation is prepared by adding the raw materials to a previously cleaned and sterilized reactor in the following order. Add 75% of the water for injection (WFI) under stirring and a constant nitrogen flow. Slowly add hydroxypropyl beta-cyclodextrin under stirring for about 10 minutes until completely dissolved. Slowly add bilastine under stirring and a constant nitrogen flow for about 30 minutes until completely dissolved. Prepare a concentrated hydrochloric acid solution with water for injection (WFI) and add the required amount under stirring to adjust the pH of the solution to 4.92 to 5.00 for about 5 to 10 minutes until completely dissolved. Verify the pH of the solution (4.92 to 5.00). Add the remaining water for injection under a constant nitrogen flow and stir for about 20 minutes.

[0223] The parenteral composition containing bilastine was filtered (0.20 μm) under laminar flow and nitrogen flow.

[0224] The bilastine parenteral composition was packaged in a 2 mL I transparent glass open ampoule. The ampoule was first cleaned and depyrogenated.

[0225] The ampoules were filled with the filtered bilastine composition (18°C to 22°C), then closed and sterilized by autoclave (121°C, 20 minutes).

[0226] Example 5. Clinical efficacy of aqueous formulations

[0227] This example and Table 1 and Figures 1 to 5 Results are presented for a single-dose, five-arm crossover, randomized, double-blind, placebo-controlled study to evaluate bilastine 12 mg intravenous (iv) and intramuscular (im) formulations compared to Peripheral anti-H1 activity of 5 mg intramuscular preparation and 20 mg oral preparation of bilastine.

[0228] Twenty-five subjects (10 males and 15 females) aged 18 to 45 years at the time of recruitment were randomized to receive:

[0229] -Placebo (intramuscular) + (oral) + placebo (intravenous)

[0230] - Bilastine (IM) + placebo (oral) + placebo (IV)

[0231] - Placebo (IM) + Placebo (OR) + Bilastine (IV)

[0232] - (IM) + Placebo (ORAL) + Placebo (IV)

[0233] - Placebo (IM) + Placebo (ORAL) + Placebo (IV).

[0234] The trial consisted of five experimental treatment periods separated by a minimum wash-out period of 7 days. All volunteers received all treatments. Finally, 23 subjects (9 males and 14 females) completed their participation in the study.

[0235] The primary objective of the study was to compare bilastine 12 mg iv, bilastine 12 mg im, bilastine 20 mg oral, and The peripheral anti-H1 activity of the 5 mg im formulation was comparable between them and relative to that of placebo.

[0236] The secondary aims of this study are to:

[0237] · Evaluate the peripheral anti-H1 activity of treatment (onset, maximum effect, and duration of maximum effect);

[0238] To evaluate the subjective feeling of itching after histamine inoculation;

[0239] Determine the pharmacokinetic profiles of the different drugs studied;

[0240] ·Evaluate potential drowsiness / somnia effects of treatment;

[0241] ·Assess the safety and tolerability of treatment.

[0242] An aqueous pharmaceutical composition of bilastine was prepared at a bilastine concentration of 1.2% w / v and a hydroxypropyl β-cyclodextrin concentration of 17% w / v. The pH was adjusted to 4.96 with concentrated HCl. The placebo solution did not contain any bilastine.

[0243] Peripheral anti-H1 activity

[0244] Subjects are subjected to wheal and flushing tests, which are the most common tools used in human antihistamine pharmacodynamic studies. The wheal and flushing test measures the drug action in the skin reaction induced by intradermal injection of histamine. The ability to suppress the wheals and flushing induced by histamine in the skin is considered to be an index of antihistamine efficacy, and is therefore an index of potential efficacy. The test relies on the ability of histamine injected through the epidermis to cause wheals and flushing, which are neurovascular responses involving reflex vasodilation (flushing) and local swelling (wheals) caused by plasma extravasation. The first stage is called wheal, which is controlled by a substance called an acute phase medium. The second stage is called flushing, which is controlled by a substance called a late phase medium. The wheal and flushing response is a typical descriptor of the two-stage allergic response seen in type 1 hypersensitivity.

[0245] In this study, antihistamine activity was assessed by measuring the wheal and flushing area induced by the histamine skin reaction test performed before and after a single daily bilastine dose. The histamine skin reaction test was performed at the following time points: pre-dose (baseline), +15 minutes, +30 minutes, +45 minutes, +1 hour, +2 hours, +4 hours, +6 hours, +9 hours, +12 hours, and +24 hours after drug administration.

[0246] The histamine skin reaction test involves inoculating 0.05 mL of a 100 mg / mL histamine solution on the ventral forearm. Each histamine inoculation is performed on one of six randomly designated areas on the ventral forearm, alternating arms each time and leaving a minimum distance of 2.0 cm between applications. Surface area is quantified using the Visitrak system (or similar system), which automatically performs the measurement in cm. 2 Calculate the area of ​​the meter.

[0247] To evaluate peripheral anti-H1 activity, the following parameters were determined:

[0248] - Onset of effect: The first time point (hours) at which wheal and flush surface areas show statistically significant differences compared to their baseline values.

[0249] -Maximum effect: Maximum percentage reduction in wheal and flush surface area.

[0250] - Time to maximum effect: The time point (hours) where the maximum percentage reduction in wheal and flush surface area is achieved.

[0251] First, the % reduction in wheal area from baseline was studied in 23 healthy subjects and monitored over a period of 15 minutes to 24 hours ( Figure 2 ). Compared to placebo, both intravenous and intramuscular bilastine showed a significant reduction in wheal area already after 15 or 30 minutes from injection, respectively. The % reduction peaked at about 2 hours and plateaued until 12 hours, after which the response began to decrease. It is important to note that the effect of im and iv bilastine in reducing wheal area was At least 3 times higher.

[0252] Next, the % reduction in flush area compared to baseline was also examined and the Significant reductions in % ( Figure 3 The % reduction peaked at about 2 hours after intravenous and intramuscular bilastine injection and began to decrease again after 12 hours. It is important to note that the reduction in flushing area caused by intramuscular and intravenous bilastine is At least 4 times higher.

[0253] Subjective feeling of itching

[0254] To assess the efficacy on the itch experienced by the subjects, a self-reported visual analogue scale (VAS) was performed for subjective itch sensation following histamine inoculation. Subjective assessments of itch were performed at the following time points: pre-dose (baseline), +15 minutes, +30 minutes, +45 minutes, +1 hour, +2 hours, +4 hours, +6 hours, +9 hours, +12 hours, and +24 hours after drug administration.

[0255] Intramuscular bilastine, intravenous bilastine and The effects of IV bilastine and IM bilastine on reducing itching sensation were similar during the first hour from injection, whereas those of IV bilastine and IM bilastine were lower in the range of 2 to 6 hours and 2 to 9 hours, respectively. About 2 times more effective ( Figure 4 ).

[0256] Subjective rating of sleepiness / somnolence

[0257] Another important aspect of the study concerns the potential side effects of the parenteral formulation of bilastine. First-generation antihistamines are known to produce significant drowsiness in patients.

[0258] To assess the drowsiness / somnolence effects of the study drug, a self-reported visual analogue scale (VAS) was performed for subjective drowsiness / somnolence effects. Subjective assessment of drowsiness / somnolence was performed at the following time points: pre-dose (baseline), +1.5 hours and +3 hours after drug administration. Performed by visual analogue scale (VAS).

[0259] Figure 5 It is shown that intramuscular At least 8 times more drowsiness was produced at 1.5 hours from injection, as perceived by the subjects, than intramuscular bilastine, and almost 4 times more drowsiness was produced at 3 hours from injection. At least 4 times higher drowsiness, as perceived by the subjects, was produced at 1.5 hours from injection than intravenous bilastine, and almost 2 times higher drowsiness was produced at 3 hours from injection than intravenous bilastine. Perhaps most interesting is the fact that both intramuscular and intravenous bilastine appeared to be as safe and well tolerated as placebo over the entire time range. In fact, no statistically significant differences were detected between placebo and im bilastine and between placebo and iv bilastine ( Figure 5 ). In contrast, in im Between im Bilastin and im A statistically significant difference was found between the Figure 5 ).

[0260] Pharmacokinetic profile

[0261] In order to obtain an accurate characterization of the kinetic curves, 5 ml blood samples were obtained at different time points.

[0262] The following pharmacokinetic parameters were determined: TM v.8.3 Drug plasma concentrations and pharmacokinetic parameters (AUC0 t 、AUC0 ∞ , C 最大 ,t 最大 ,t 1 / 2 , Kel, Cl, Vd).

[0263] The data in Table 1 show the pharmacokinetic parameters of various treatments used in clinical trials.

[0264] Table 1. Pharmacokinetic data related to treatments from clinical trials.

[0265]

[0266] As shown in Table 1 and Figure 1 As can be appreciated from the Figures, all drug forms and each route of administration (oral, im and iv) of bilastine had similar AUCs (area under the curve), indicating similar body exposure to the drug. 最大 and t 最大 There were differences among the three formulations depending on the route of administration, with C of im and iv bilastine being higher than that of oral administration. 最大 Much higher and t 最大 Furthermore, across all drug forms and routes of administration, the elimination half-life (t 1 / 2 ) remained very similar and stable, indicating that each form of bilastine is very stable.

[0267] at last, Shows a very similar t to imbilastine 最大 , indicating that the im absorption is similar.

Claims

1. An aqueous parenteral pharmaceutical composition comprising: a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, and b) 10% w / v to 30% w / v of a β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof, and wherein the pH of the composition is from 3.0 to 7.2, including both the lower and upper limits of the range, and wherein parenteral is selected from intravenous or intramuscular.

2. The pharmaceutical composition according to claim 1, wherein the composition does not contain a gelling agent.

3. A pharmaceutical composition according to any one of claims 1 to 2, wherein the composition consists of: a) 0.96% w / v to 2.60% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, b) 10% w / v to 30% w / v of β-cyclodextrin selected from the group consisting of unmodified β-cyclodextrin, C1-C6 alkyl-β-cyclodextrin, C1-C6 hydroxyalkyl-β-cyclodextrin, C1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C1-C6 sulfoalkyl ether β-cyclodextrin, and mixtures thereof, c) a pH adjusting agent for providing a pH value of 3.0 to 7.2, including both the lower and upper limits of the range, d) water for injection, and e) optionally, one or more pharmaceutically acceptable parenteral excipients or carriers selected from the group consisting of preservatives, tonicity agents, buffers, antioxidants, chelating agents, fillers, solubilizers, surfactants, co-solvents, and mixtures thereof, including antimicrobial preservatives and chemical preservatives.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the composition comprises 1.0% w / v to 1.4% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the composition comprises 1.1% w / v to 1.3% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the composition comprises 1.14% w / v to 1.26% w / v, or a pharmaceutically acceptable salt or solvate thereof.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the composition comprises 10% w / v to 25% w / v of the β-cyclodextrin.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the composition comprises 12% w / v to 22% w / v of the β-cyclodextrin.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the composition comprises 15% w / v to 20% w / v of the β-cyclodextrin.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the β-cyclodextrin is a C1-C6 hydroxyalkyl β-cyclodextrin.

11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the β-cyclodextrin is hydroxypropyl β-cyclodextrin.

12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pH value of the composition is 4.0 to 7.

0.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the pH value of the composition is 4.0 to 6.

0.

14. A pharmaceutical composition according to any one of claims 1 to 13, wherein the composition comprises: a) 1.0% w / v to 1.4% w / v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, and b) 10% w / v to 25% w / v of C1-C6 hydroxyalkyl β-cyclodextrin, such as hydroxypropyl β-cyclodextrin, and The pH value of the composition is 4 to 6, including both the lower and upper limits of the range.

15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the volume of each unit dose is 0.5 to 1.5 mL.

16. The pharmaceutical composition according to any one of claims 1 to 15, wherein the volume of each unit dose is 0.8 to 1.5 mL.

17. The pharmaceutical composition according to any one of claims 1 to 16, wherein the volume of each unit dose is 0.8 to 1.2 mL.

18. The pharmaceutical composition according to any one of claims 1 to 17, wherein the composition is a once-daily composition.

19. A pharmaceutical composition according to any one of claims 1 to 18 for use as a medicament.

20. A pharmaceutical composition according to any one of claims 1 to 18 for use in the treatment and / or prevention of allergic diseases or disorders or allergic symptoms.

21. A pharmaceutical composition for use according to any one of claims 19 or 20 for the treatment and / or prevention of acute type I hypersensitivity reactions.

22. A pharmaceutical composition for use according to any one of claims 19 to 21 for the treatment and / or prevention of rhinitis, conjunctivitis, rhinoconjunctivitis, hay fever, dermatitis, eczema, erythema, pruritus, itching, urticaria, asthma, allergic reactions, acute urticaria, chronic urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity reactions, angioedema, food allergies or drug allergies.

23. A pharmaceutical composition for use according to any one of claims 19 to 22, wherein the composition is administered once daily.

24. Use of a pharmaceutical composition according to any one of claims 1 to 18 in the preparation of a medicament for the treatment and / or prevention of an allergic disease or disorder or an allergic symptom.

25. Use according to claim 24, for the preparation of a medicament for the treatment and / or prevention of acute type I hypersensitivity reactions.

26. Use according to any one of claims 24 or 25, for the preparation of a medicament for the treatment and / or prevention of rhinitis, conjunctivitis, rhinoconjunctivitis, hay fever, dermatitis, eczema, erythema, pruritus, itching, urticaria, asthma, allergic reactions, acute urticaria, chronic urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity reactions, angioedema, food allergies or drug allergies.

27. The use according to any one of claims 24 to 26, wherein the medicament is administered once daily.

28. A method for treating and / or preventing an allergic disease or disorder or an allergic symptom, the method comprising administering to a subject in need of such treatment and / or prevention a therapeutically effective amount of a pharmaceutical composition according to any one of claims 1 to 18.

29. The method according to claim 28, wherein the treatment and / or prevention is the treatment and / or prevention of acute type I hypersensitivity reactions.

30. The method according to any one of claims 28 or 29, wherein the treatment and / or prevention is the treatment and / or prevention of rhinitis, conjunctivitis, rhinoconjunctivitis, hay fever, dermatitis, eczema, erythema, pruritus, itching, urticaria, asthma, allergic reaction, acute urticaria, chronic urticaria, acute exacerbation of chronic urticaria, immediate hypersensitivity reaction, angioedema, food allergy or drug allergy.

31. The method according to any one of claims 28 to 30, which is administered once daily.

Citation Information

Patent Citations

  • New piperidine derivatives of benzimidazole as antihistanminic and antiallergic agents

    EP0580541A1

  • Benzimidazole derivatives with antihistaminic activity

    EP0818454A1

  • A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine

    EP1005865B1

  • New benzimidazole derivatives as antihistamine agents

    EP3040334A1

  • Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent

    WO2019141563A1